Table 3. Relation between patient characteristics and Ki-67 score.
| Characteristic | Number of patients (%) | Median Ki-67 score % (interquartile range) | P-value |
|---|---|---|---|
| All | 179 | 40 (24–52) | |
| Age at diagnosis | 0.022* | ||
| Median (years) | 68 | ||
| Interquartile range (years) | 60–74 | ||
| Body mass index (kg/m2) | 0.663 | ||
| <25 | 22 (12) | 44 (26–58) | |
| 25–29.9 | 35 (20) | 28 (17–47) | |
| ≥30 | 64 (36) | 41 (26–51) | |
| Missing data | 58 (32) | 43 (28–55) | |
| Grade | |||
| 1 | 39 (22) | 23 (10–39) | <0.0001**** |
| 2 | 36 (20) | 41 (26–50) | |
| 3 | 104 (58) | 44 (30–55) | |
| Stage | 0.014** | ||
| 1 | 108 (60) | 36 (22–50) | |
| 2 | 22 (12) | 37 (24–55) | |
| 3 | 42 (24) | 44 (29–56) | |
| 4 | 6 (3) | 54 (45–67) | |
| Missing data | 1 (1) | 17 (17–17) | |
| Histological type | 0.246 | ||
| Endometrioid | 116 (65) | 37 (23–51) | |
| Non-endometrioida | 63 (35) | 44 (28–54) | |
| Lymphovascular space invasion | 0.138 | ||
| Absent | 93 (52) | 37 (22–50) | |
| Present | 70 (39) | 42 (25–55) | |
| Missing data | 16 (9) | 45 (31–53) | |
| Depth of myometrial invasion | 0.030* | ||
| <50% | 83 (46) | 32 (20–50) | |
| ≥50% | 92 (51) | 43 (28–53) | |
| Missing data | 4 (2) | 42 (33–51) | |
| Any adjuvant therapy | 0.031* | ||
| No | 61 (34) | 32 (22–49) | |
| Yesb | 102 (57) | 44 (27–55) | |
| Missing data | 16 (9) | 35 (26–45) |
Ki-67 expression positively correlated with age at the time of surgery, grade, and stage of endometrial cancer. Higher scores were seen in tumors with >50% myoinvasion compared with more superficially invasive cancers and women receiving adjuvant therapy. There was no association between Ki-67 and body mass index, histological type of endometrial cancer, and lymphovascular space invasion (P>0.05).
Grade 3 endometrioid tumors are classified within the endometrioid subtype. Non-endometrioid tumors include serous, clear cell, carcinosarcomas, mixed, and undifferentiated cancers.
Adjuvant treatment included external beam radiotherapy (44, 25%), vaginal brachytherapy (21, 12%) or both (25, 14%), and/or chemotherapy (39, 22%), which was single-agent carboplatin (2, 1%) or carboplatin/paclitaxel-based (29, 16%). Data on chemotherapy regime absent in 8 (5%) of cases. *p≤0.05, **p≤0.01, ***p≤0.001, ****p≤0.0001.